Next Article in Journal
Aged Lens Epithelial Cells Suppress Proliferation and Epithelial–Mesenchymal Transition-Relevance for Posterior Capsule Opacification
Next Article in Special Issue
NF-κB p65 Attenuates Cardiomyocyte PGC-1α Expression in Hypoxia
Previous Article in Journal
Possible Underlying Mechanisms for the Renoprotective Effect of Retinoic Acid-Pretreated Wharton’s Jelly Mesenchymal Stem Cells against Renal Ischemia/Reperfusion Injury
Previous Article in Special Issue
Calreticulin and the Heart
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay

1
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy
2
Department of Angiocardioneurology, IRCCS Neuromed, 86077 Pozzilli, Italy
3
Cardiology Division, Santa Maria Goretti Hospital, 04100 Latina, Italy
*
Author to whom correspondence should be addressed.
Cells 2022, 11(13), 2000; https://doi.org/10.3390/cells11132000
Submission received: 13 May 2022 / Revised: 17 June 2022 / Accepted: 20 June 2022 / Published: 22 June 2022
(This article belongs to the Special Issue Cardiac Growth Control and Heart Cell Death)

Abstract

Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer cause of death in DOX-treated patients. Although many different molecular mechanisms explaining the cardiac derangements induced by DOX were identified in past decades, the translation to clinical practice has remained elusive to date. This review examines the current understanding of DOX-induced cardiomyopathy (DCM) with a focus on mitochondria, which were increasingly proven to be crucial determinants of DOX-induced cytotoxicity. We discuss DCM pathophysiology and epidemiology and DOX-induced detrimental effects on mitochondrial function, dynamics, biogenesis, and autophagy. Lastly, we review the current perspectives to contrast the development of DCM, which is still a relatively diffused, invalidating, and life-threatening condition for cancer survivors.
Keywords: DOX; anthracycline; cardiomyopathy; mitochondria; heart DOX; anthracycline; cardiomyopathy; mitochondria; heart

Share and Cite

MDPI and ACS Style

Schirone, L.; D’Ambrosio, L.; Forte, M.; Genovese, R.; Schiavon, S.; Spinosa, G.; Iacovone, G.; Valenti, V.; Frati, G.; Sciarretta, S. Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. Cells 2022, 11, 2000. https://doi.org/10.3390/cells11132000

AMA Style

Schirone L, D’Ambrosio L, Forte M, Genovese R, Schiavon S, Spinosa G, Iacovone G, Valenti V, Frati G, Sciarretta S. Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. Cells. 2022; 11(13):2000. https://doi.org/10.3390/cells11132000

Chicago/Turabian Style

Schirone, Leonardo, Luca D’Ambrosio, Maurizio Forte, Riccardo Genovese, Sonia Schiavon, Giulia Spinosa, Giuliano Iacovone, Valentina Valenti, Giacomo Frati, and Sebastiano Sciarretta. 2022. "Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay" Cells 11, no. 13: 2000. https://doi.org/10.3390/cells11132000

APA Style

Schirone, L., D’Ambrosio, L., Forte, M., Genovese, R., Schiavon, S., Spinosa, G., Iacovone, G., Valenti, V., Frati, G., & Sciarretta, S. (2022). Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. Cells, 11(13), 2000. https://doi.org/10.3390/cells11132000

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop